Breast Cancer

Taking Zoledronic Acid Less Often After the First Year of Treatment Is Safe for Women with Metastatic Breast Cancer

ASCO Annual Meeting
May 30, 2014

According to new findings from a phase III clinical trial, women taking zoledronic acid (Zometa) for breast cancer that has spread to the bone, called metastases, can safely scale back to a once-every-three-months schedule after finishing a year of monthly treatments.

Pages

Subscribe to RSS - Breast Cancer